Nuvalent, Inc. Stock Price, News & Analysis

Nuvalent (NUVL) announced updated Phase 1 data for its ALK-selective inhibitor NVL-655 and ROS1-selective inhibitor zidesamtinib at ESMO Congress 2024. Key highlights:

- NVL-655 showed 38% overall response rate (ORR) in heavily pre-treated ALK+ NSCLC patients, with 9.2 month median duration of response (DOR)

- Zidesamtinib demonstrated 38% ORR in ROS1+ NSCLC patients previously treated with ROS1 TKIs, with median DOR not reached

- Both drugs showed promising intracranial activity and favorable safety profiles

- Phase 2 trials with registrational intent are ongoing for both drugs in TKI-naïve and pre-treated patients

The company believes these results support the potential for NVL-655 and zidesamtinib to become best-in-class therapies for ALK+ and ROS1+ NSCLC, respectively.

Nuvalent, a clinical-stage biopharmaceutical company (Nasdaq: NUVL), has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 5, 2024, at 1:05 p.m. ET in New York City.

Key details:

• CEO James Porter, Ph.D., and CFO Alexandra Balcom will participate in a fireside chat
• A live webcast will be available on the company's website
• The webcast will be archived for 30 days after the presentation

Nuvalent focuses on developing precisely targeted therapies for clinically proven kinase targets in cancer. This conference participation provides an opportunity for investors and stakeholders to gain insights into the company's progress and future plans.

Nuvalent (Nasdaq: NUVL) reported Q2 2024 financial results and pipeline progress. Key highlights include:

- $658.0 million in cash, cash equivalents, and marketable securities, expected to support operations into 2027

- Ongoing enrollment in Phase 2 trials for NVL-655 (ALK program) and zidesamtinib (ROS1 program)

- FDA breakthrough therapy designation granted for both NVL-655 and zidesamtinib

- Initiation of HEROEX-1 trial for NVL-330 (HER2 program)

- Plans to present updated Phase 1 data at ESMO Congress 2024

Financial results for Q2 2024:

- R&D expenses: $49.2 million

- G&A expenses: $16.0 million

- Net loss: $57.2 million

Nuvalent aims to deliver at least one pivotal dataset in 2025 towards potential product approval in 2026.

Nuvalent (Nasdaq: NUVL) has announced the initiation of HEROEX-1, a Phase 1a/1b clinical trial evaluating its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer (NSCLC). The trial aims to assess the safety, tolerability, and preliminary anti-tumor activity of NVL-330, as well as determine the recommended Phase 2 dose and characterize its pharmacokinetic profile.

NVL-330 has shown potential in preclinical studies to maintain activity against HER2 exon 20 mutations, be selective for HER2 versus wild-type EGFR, and demonstrate brain penetrance. These characteristics address key needs in HER2-mutant NSCLC treatment, for which there are currently no approved tyrosine kinase inhibitors (TKIs).

This marks Nuvalent's third program to enter clinical development in under three years, highlighting the company's commitment to rapid progress in developing targeted cancer therapies.

Nuvalent (Nasdaq: NUVL) announced upcoming presentations of updated data from two clinical trials at the ESMO Congress 2024 in Barcelona. The presentations will focus on:

1. NVL-655, an ALK-selective inhibitor, from the ALKOVE-1 Phase 1/2 trial in ALK-positive solid tumors.

2. Zidesamtinib (NVL-520), a ROS1-selective inhibitor, from the ARROS-1 Phase 1/2 trial in ROS1 fusion-positive solid tumors.

Additionally, Nuvalent will present new preclinical data on zidesamtinib's intracranial activity. These presentations highlight Nuvalent's progress in developing targeted therapies for clinically proven kinase targets in cancer.

Nuvalent, a clinical-stage biotech firm, has promoted Dr. Henry Pelish to Chief Scientific Officer. In this role, Dr. Pelish will continue to oversee discovery and early-stage development initiatives. Dr. Pelish, who joined Nuvalent in 2018, has been instrumental in developing three novel kinase inhibitors, two of which have shown preliminary clinical proof-of-concept. CEO Dr. James Porter praised Pelish's contributions to the company's innovative approach to cancer therapy. Dr. Pelish holds a Ph.D. in chemistry from Harvard and has over 15 years of experience in cancer biology and chemistry. He expressed excitement about advancing Nuvalent's mission to deliver targeted therapies for cancer patients.

Nuvalent, a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with CEO James Porter and CFO Alexandra Balcom on June 5, 2024, at 4:30 p.m. ET. The session will be live-streamed and available on the company's website for 30 days.

Nuvalent announced that the FDA has granted breakthrough therapy designation (BTD) for NVL-655, a novel ALK-selective tyrosine kinase inhibitor (TKI) designed to treat locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) in patients previously treated with two or more ALK TKIs. ALK rearrangements occur in up to 5% of metastatic NSCLCs, with 40% of these patients presenting brain metastases at diagnosis, and 50% developing resistance mutations after treatment. NVL-655 aims to address these challenges with brain-penetrant properties and minimal off-target CNS adverse events. The BTD is based on Phase 1 trial results, with Phase 2 enrollment ongoing. Nuvalent plans an update from the ALKOVE-1 trial in the second half of 2024.

Nuvalent, a clinical-stage biopharmaceutical company, highlighted pipeline progress, reiterated key milestones, and reported strong financial results for the first quarter of 2024. The company is focused on developing novel kinase inhibitors for cancer treatment, with anticipated milestones including updates from ongoing clinical trials and a potential first approval in 2026. Nuvalent's ROS1 and ALK programs are progressing well, with preclinical data demonstrating the effectiveness of their inhibitors. The company also plans to initiate a Phase 1 trial for its HER2 program in 2024. Financially, Nuvalent has a solid cash position expected to fund operations into 2027.